{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:12:49Z","timestamp":1782929569460,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.05.021","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:32:45Z","timestamp":1750174365000},"page":"1140-1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prostate Cancer Outcomes in Immunocompromised Patients: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"given":"Francesco","family":"Sanguedolce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Uleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Chernysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Roqu\u00e9 Figuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Territo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.05.021_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.021_b0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.05.021_b0015","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.14336\/AD.2019.1028","article-title":"Practical approaches to treat ED in PDE5i nonresponders","volume":"11","author":"Cai","year":"2020","journal-title":"Aging Dis"},{"key":"10.1016\/j.euo.2025.05.021_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085179","article-title":"The role of prostatitis in prostate cancer: meta-analysis","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2025.05.021_b0025","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.05.021_b0030","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.05.021_b0035","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1158\/0008-5472.CAN-07-6603","article-title":"Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer","volume":"68","author":"Basu","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.05.021_b0040","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1541-7786.MCR-14-0136","article-title":"Cyclosporin A promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species","volume":"12","author":"Zhou","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.euo.2025.05.021_b0045","doi-asserted-by":"crossref","first-page":"57.e9","DOI":"10.1016\/j.urolonc.2015.08.020","article-title":"Prostate-specific antigen screening and prostate cancer treatment in renal transplantation candidates: a survey of U.S. transplantation centers","volume":"34","author":"Gin","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.021_b0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ajt.13978","article-title":"Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines","volume":"17","author":"Acuna","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.euo.2025.05.021_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.05.021_b0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.23487","article-title":"Cancer risk in people infected with human immunodeficiency virus in the United States","volume":"123","author":"Engels","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2025.05.021_b0065","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.021_b0070","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.05.021_b0075","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2015","journal-title":"ScienceOpen"},{"key":"10.1016\/j.euo.2025.05.021_b0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JU.0000000000000001","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"201","author":"Assel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.05.021_b0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djz221","article-title":"Prostate cancer outcomes following solid-organ transplantation: a SEER-Medicare analysis","volume":"112","author":"Liauw","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2025.05.021_b0090","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.32299","article-title":"Survival among solid organ transplant recipients diagnosed with cancer compared to nontransplanted cancer patients\u2014a nationwide study","volume":"146","author":"Benoni","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2025.05.021_b0095","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.31782","article-title":"Survival after a cancer diagnosis among solid organ transplant recipients in the United States","volume":"125","author":"D\u2019Arcy","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.05.021_b0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bju.15002","article-title":"Prostate cancer in kidney transplant recipients\u2014a nationwide register study","volume":"125","author":"Bratt","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.05.021_b0105","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.1002\/cam4.5571","article-title":"Treatment patterns and survival of low and intermediate-risk prostate cancer in end-stage kidney disease: a retrospective population cohort study","volume":"12","author":"Sarabu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2025.05.021_b0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1742","article-title":"HIV infection, cancer treatment regimens, and cancer outcomes among elderly adults in the United States","volume":"5","author":"Coghill","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.05.021_b0115","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1055-9965.EPI-14-1079","article-title":"Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers","volume":"24","author":"Marcus","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euo.2025.05.021_b0120","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1055-9965.EPI-10-0741","article-title":"Reduced risk of prostate cancer in U.S. men with AIDS","volume":"19","author":"Shiels","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euo.2025.05.021_b0125","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cncr.32158","article-title":"Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base","volume":"125","author":"Coghill","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.05.021_b0130","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1158\/1055-9965.EPI-16-0964","article-title":"Excess mortality among HIV-infected individuals with cancer in the United States","volume":"26","author":"Coghill","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euo.2025.05.021_b0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaoncol.2018.4934","article-title":"Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients","volume":"5","author":"Tichelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.05.021_b0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/acr.22997","article-title":"Impact of rheumatoid arthritis on the mortality of elderly patients who develop cancer: a population-based study","volume":"69","author":"Nayak","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.euo.2025.05.021_b0145","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/acr.24890","article-title":"Risk of prostate cancer in US veterans with rheumatoid arthritis","volume":"75","author":"Wheeler","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.euo.2025.05.021_b0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.euf.2018.05.010","article-title":"Management of localised prostate cancer in kidney transplant patients: a systematic review from the EAU Guidelines on Renal Transplantation Panel","volume":"4","author":"Hevia","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.05.021_b0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JU.0000000000000207","article-title":"Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer","volume":"202","author":"Aminsharifi","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.05.021_b0160","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bju.13612","article-title":"Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo","volume":"119","author":"Flamiatos","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.05.021_b0165","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer","volume":"188","author":"Haffner","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.euo.2025.05.021_b0170","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/jid.2015.312","article-title":"Melanoma risk and survival among organ transplant recipients","volume":"135","author":"Robbins","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.euo.2025.05.021_b0175","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/TP.0b013e3181a238f6","article-title":"De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population","volume":"87","author":"Miao","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.euo.2025.05.021_b0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1681\/ASN.2018090906","article-title":"Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant","volume":"30","author":"Au","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.euo.2025.05.021_b0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00345-023-04294-2","article-title":"Active surveillance in renal transplant patients with prostate cancer: a multicentre analysis","volume":"41","author":"Soeterik","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.05.021_b0190","first-page":"69","article-title":"Chronic inflammation: a common and important factor in the pathogenesis of neoplasia","volume":"56","author":"Schottenfeld","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.05.021_b0195","doi-asserted-by":"crossref","first-page":"9336","DOI":"10.1128\/JVI.78.17.9336-9342.2004","article-title":"Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat","volume":"78","author":"Guo","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.euo.2025.05.021_b0200","doi-asserted-by":"crossref","first-page":"12310","DOI":"10.1074\/jbc.M211167200","article-title":"Human immunodeficiency virus type-1 Tat\/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription","volume":"278","author":"Harrod","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.euo.2025.05.021_b0205","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00002030-199606001-00003","article-title":"Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus\/tat transgenic mice","volume":"10","author":"Corallini","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.euo.2025.05.021_b0210","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41585-023-00846-8","article-title":"A clinical overview of people living with HIV and genitourinary cancer care","volume":"21","author":"Suk-Ouichai","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.05.021_b0215","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/cncr.29324","article-title":"Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients","volume":"121","author":"Shiels","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.05.021_b0220","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/rheumatology\/ker143","article-title":"Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer","volume":"50","author":"Ji","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.euo.2025.05.021_b0225","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.euo.2025.05.021_b0230","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","article-title":"Revisiting immunotherapy: a focus on prostate cancer","volume":"80","author":"Cha","year":"2020","journal-title":"Cancer Res"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:23:37Z","timestamp":1758079417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001634"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.021","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Outcomes in Immunocompromised Patients: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}